Y-mAbs Therapeutics, Inc. is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad, advanced product pipeline, including two pivotal-stage candidates—naxitamab and omburtamab—which target tumors that express GD2 and B7-H3, respectively. Y-mAbs is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, or R/R, high-risk neuroblastoma, or NB, and radiolabeled omburtamab for the treatment of pediatric patients with central nervous system, or CNS, leptomeningeal metastases, or LM, from NB. NB is a rare and almost exclusively pediatric cancer that develops in the sympathetic nervous system and CNS/LM is a rare and usually fatal complication of NB in which the disease spreads to the membranes, or meninges, surrounding the brain and spinal cord in the CNS. Y-mAbs expects to submit a BLA for each of its two lead product candidates in 2019, with a goal of receiving FDA approval in 2020.